γ-secretase modulation with Aβ42-lowering nonsteroidal anti-inflammatory drugs and derived compounds

Neurodegenerative Diseases

Volumn 3, Issue 4-5, 2006, Pages 298-304

  Czirr, Eva ^a   Weggen, Sascha ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Secretase; Alzheimer's disease; Amyloid peptide; Ibuprofen; Nonsteroidal anti inflammatory drugs

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CELECOXIB; FENOFIBRATE; FENOPROFEN; FLURBIPROFEN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; IBUPROFEN; INDOMETACIN; ISOPROTEIN; MECLOFENAMIC ACID; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; NOTCH RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROSTAGLANDIN SYNTHASE; ROFECOXIB; SULINDAC SULFIDE;

ALZHEIMER DISEASE; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; FAMILIAL DISEASE; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SENILE PLAQUE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; THEORETICAL STUDY; UNSPECIFIED SIDE EFFECT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 33750198829     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000095270     Document Type: Conference Paper

References (34)

1. Wancata J, Musalek M, Alexandrowicz R, Krautgartner M: Number of dementia sufferers in Europe between the years 2000 and 2050. Eur Psychiatry 2003;18:306-313.
2. Golde TE: Alzheimer disease therapy: can the amyloid cascade be halted? J Clin Invest 2003;111:11-18.
3. Selkoe DJ: Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 2001;81:741-766.
4. Beher D, Graham SL: Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease. Expert Opin Investig Drugs 2005;14:1385-1409.
5. Haass C: Take five - BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J 2004;23:483-488.
6. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH: A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001;414:212-216.
7. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T: Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
8. Etminan M, Gill S, Samii A: Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003;327:128.
9. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE: NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003;112:440-449.
10. Morihara T, Chu T, Ubeda O, Beech W, Cole GM: Selective inhibition of Abeta42 production by NSAID R-enantiomers. J Neurochem 2002;83:1009-1012.
11. 1-42 secretion. J Med Chem 2005;48:5705-5720.
12. Takahashi Y, Hayashi I, Tominari Y, Rikimaru K, Morohashi Y, Kan T, Natsugari H, Fukuyama T, Tomita T, Iwatsubo T: Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J Biol Chem 2003;278:18664-18670.
13. Zhou Y, Su Y, Li B, Liu F, Ryder JW, Wu X, Gonzalez-DeWhitt PA, Gelfanova V, Hale JE, May PC, Paul SM, Ni B: Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 2003;302:1215-1217.
14. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, Citron M, Landreth G: Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 2003;23:7504-7509.
15. Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M, Merit S, Ozols VV, Anastasiadis PZ, Das P, Fauq A, Koo EH, Golde TE: Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med 2005;11:545-550.
16. Gasparini L, Rusconi L, Xu H, Del Soldato P, Ongini E: Modulation of beta-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures. J Neurochem 2004;88:337-348.
17. Beher D, Clarke EE, Wrigley JD, Martin AC, Nadin A, Churcher I, Shearman MS: Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J Biol Chem 2004;279:43419-43426.
18. Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, Koo EH: Abeta42-lowering non-steroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem 2003;278:30748- 30754.
19. Tegeder I, Pfeilschifter J, Geisslinger G: Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001;15:2057-2072.
20. Sagi SA, Weggen S, Eriksen J, Golde TE, Koo EH: The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production. J Biol Chem 2003;278:31825-31830.
21. Leuchtenberger S, Kummer MP, Kukar T, Czirr E, Teusch N, Sagi SA, Berdeaux R, Pietrzik CU, Ladd TB, Golde TE, Koo EH, Weggen S: Inhibitors of Rho-kinase modulate amyloid-beta (Abeta) secretion but lack selectivity for Abeta42. J Neurochem 2006;96:355-365.
22. Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, Golde TE, Koo EH: Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem 2003;278:31831-31837.
23. Berezovska O, Lleo A, Herl LD, Frosch MP, Stern EA, Bacskai BJ, Hyman BT: Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein. J Neurosci 2005;25:3009-3017.
24. Lleo A, Berezovska O, Herl L, Raju S, Deng A, Bacskai BJ, Frosch MP, Irizarry M, Hyman BT: Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med 2004;10:1065-1066.
25. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM: Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000;20:5709-5714.
26. Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, Gordon MN: Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 2002;22:2246-2254.
27. Sung S, Yang H, Uryu K, Lee EB, Zhao L, Shineman D, Trojanowski JQ, Lee VM, Pratico D: Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am J Pathol 2004;165:2197-2206.
28. Lim GP, Yang F, Chu T, Gahtan E, Ubeda O, Beech W, Overmier JB, Hsiao-Ashec K, Frautschy SA, Cole GM: Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 2001;22:983-991.
29. Lanz TA, Fici GJ, Merchant KM: Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J Pharmacol Exp Ther 2005;312:399-406.
30. Gasparini L, Ongini E, Wenk G: Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J Neurochem 2004;91:521-536.
31. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P, et al: Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-1611.
32. Imbimbo BP: The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease. Expert Opin Investig Drugs 2004;13:1469-1481.
33. Tabet N, Feldmand H: Ibuprofen for Alzheimer's disease. Cochrane Database Syst Rev 2003:CD004031.
34. http://www.myriad.com/alzheimers/phase2_ad.php